OR WAIT null SECS
Pfizer’s new format of ibuprofen (AdvilR Liqui-GelsR Minis) uses Catalent’s softgel technology to deliver the formulation in a more concentrated fill, resulting in smaller capsules.
Catalent Pharma Solutions, provider of advanced drug-delivery technologies, announced that it has entered into an exclusive long-term supply agreement to produce Pfizer’s newly launched over-the-counter (OTC) pain relief product-Advil Liqui-Gels Minis (ibuprofen)-which uses Catalent’s softgel platform OptiGel Mini technology.
Catalent has collaborated with Pfizer for 20 years on the development and manufacture of Advil Liqui-Gels. The new format, Advil Liqui-Gels Minis, delivers the formulation in a more concentrated fill, resulting in smaller capsules that are easier to swallow. Smaller capsules address the problem of swallowing difficulties often experienced by pediatric and geriatric consumers.
Under the arrangement, Catalent’s St. Petersburg, Florida, facility has already formulated and is manufacturing the new format for Pfizer. The new product was recently launched in the US market.